*Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Center for Innovative and Translational Medicine, Kochi University Medical School, Kochi, Japan; and Departments of Gastroenterology, Digestive Tract Surgery, and Pathology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
*Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada; Center for Innovative and Translational Medicine, Kochi University Medical School, Kochi, Japan; and Departments of Gastroenterology, Digestive Tract Surgery, and Pathology, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
J Leukoc Biol. 2015 Oct;98(4):671-81. doi: 10.1189/jlb.5A1014-509RR. Epub 2015 Jul 10.
Human Slan DCs have been studied in patients with psoriasis, rheumatoid arthritis, cancer, and autoimmune diseases. In this study, we investigated the frequency, phenotype, and function of Slan DCs in blood, colon, as well as mLNs of patients with IBD. We first show that the frequency of circulating CD14(dull)Slan DCs was reduced in CD patients refractory to immunosuppressive drugs or TNF-α blockers relative to untreated CD, UC, and healthy subjects. In blood of CD patients, Slan DCs expressed CD172a, as detected by CD47 fusion protein binding, when compared with its lack of expression in control subjects. Next, we demonstrate that CD172a(+)Slan DCs that produced IL-1β and TNF-α accumulated in mLNs and colons of CD patients. The CD172a(+)Slan DCs up-regulated their expression of CD14 in CD tissues and the proinflammatory cytokines were produced in CD14(bright)CD172a(+)Slan DCs. By contrast, no difference was noted in the frequency of Slan DCs between inflamed, noninflamed colonic mucosa of UC patients and control, non-IBD donors. Finally, the percentage of cytokine-producing Slan DCs also augmented in response to TLR2 and NOD2 in in vitro stimulation in PBMCs of CD, but not UC, patients. In conclusion, we propose that proinflammatory CD14(bright)CD172a(+)Slan DCs are a distinguishing feature between CD and UC, as these cells accumulate uniquely in mLNs and colonic mucosa of CD patients. Thus, Slan DCs may contribute to CD immunopathogenesis.
人类 Slan DC 已在银屑病、类风湿关节炎、癌症和自身免疫性疾病患者中进行了研究。在这项研究中,我们研究了 IBD 患者血液、结肠和 mLN 中 Slan DC 的频率、表型和功能。我们首先表明,与未治疗的 CD、UC 和健康受试者相比,对免疫抑制剂或 TNF-α 阻滞剂无反应的 CD 患者循环中 CD14(暗)Slan DC 的频率降低。在 CD 患者的血液中,与对照相比,Slan DC 通过 CD47 融合蛋白结合表达 CD172a。接下来,我们证明在 CD 患者的 mLN 和结肠中积累了产生 IL-1β 和 TNF-α 的 CD172a(+)Slan DC。CD172a(+)Slan DC 在 CD 组织中上调 CD14 的表达,并且在 CD14(bright)CD172a(+)Slan DC 中产生促炎细胞因子。相比之下,UC 患者和对照非 IBD 供体的炎症和非炎症结肠黏膜之间的 Slan DC 频率没有差异。最后,在体外刺激 CD、但不是 UC 患者的 PBMC 中,产生细胞因子的 Slan DC 的百分比也增加。总之,我们提出促炎性 CD14(bright)CD172a(+)Slan DC 是 CD 和 UC 之间的区别特征,因为这些细胞仅在 CD 患者的 mLN 和结肠黏膜中积累。因此,Slan DC 可能有助于 CD 的免疫发病机制。